Cite
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC.
MLA
Schmid, P., et al. “VP7-2021: KEYNOTE-522: Phase III Study of Neoadjuvant Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs. Placebo for Early-Stage TNBC.” Annals of Oncology, vol. 32, no. 9, Sept. 2021, pp. 1198–200. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.06.014.
APA
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P. A., Cardoso, F., Ding, Y., Tryfonidis, K., Aktan, G., Karantza, V., & O’Shaughnessy, J. (2021). VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Annals of Oncology, 32(9), 1198–1200. https://doi.org/10.1016/j.annonc.2021.06.014
Chicago
Schmid, P., J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, et al. 2021. “VP7-2021: KEYNOTE-522: Phase III Study of Neoadjuvant Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs. Placebo for Early-Stage TNBC.” Annals of Oncology 32 (9): 1198–1200. doi:10.1016/j.annonc.2021.06.014.